LONDON, Aug. 31, 2016 /PRNewswire/ -- The global biopharmaceutical Industry has come a long way since its first drug- Humulin was approved in 1982. Today hundreds of biopharmaceuticals have already been approved and many more are in late stages of clinical development. These drugs have not only advanced the prevention and treatment of a number of life threatening diseases but have also provided the thrust for the continued success of the pharmaceutical industry.
Under mounting economic pressures to increase their outputs, pharmaceutical manufacturers have embraced biopharmaceuticals as a means to maintain flow in their drying pipelines. Bringing a biopharmaceutical, however, represents a very risky proposition as out of every ten drugs that enter the clinical phases, only three manage to gain market approval. But the industry's multibillion dollar revenues and strong growth rates in previous years bears a testimony to the fact that the ones that finally do get approval represent goldmines for investors.
Although factors like biosimilar entry and cost containment in the developed markets are likely to restrain the growth of this market in the coming years, IMARC expects that with their high potency and ability to attack targets beyond the reach of traditional small molecule drugs, biopharmaceuticals provide the industry with a huge scope for future growth. A rich late stage pipeline and increasing demand in emerging markets are also expected to be major drivers in the coming years.
The study covers the market analysis of various segments and sub-segments of the biopharmaceutical industry based on class and key indicative areas. Recombinant proteins currently represent the biggest segment on the basis of class accounting for the majority of the global biopharmaceutical sales. Recombinant proteins are followed by monoclonal antibodies and purified proteins. On the basis of key indicative and therapeutic application areas for biopharmaceuticals, autoimmune diseases represent the largest segment followed by oncology. With most of the current and future monoclonal antibodies targeted against autoimmune diseases such as rheumatoid arthritis and oncology, autoimmune diseases and oncology will continue to represent the dominant indications for biopharmaceuticals over the next five years.
The biopharmaceutical market is largely dominated by the US accounting for nearly half of the total global sales. The other top markets include Germany, Japan, France, Italy, Spain, UK and Canada. Moreover, increasing disposable incomes and a larger access to healthcare insurance, the market for biopharmaceuticals is also expected to expand and offer great opportunities and growth prospects across various emerging markets over the next few years. The report has also provided a robust analysis of the key players operating in the global biopharmaceutical market. Some of the key players analysed in this report include: Roche, Amgen, Novo Nordisk, AbbVie and Sanofi.
IMARC's new report "Global Biopharmaceutical Market Report & Forecast (2016-2021)" gives a deep insight into the global biopharmaceutical market. The research study serves as an analytical as well as a statistical tool to understand the strengths, weaknesses, opportunities, threats, market trends, geographical structure, therapeutic structure, competitive structure and the outlook of the global biopharmaceutical market till 2021. This report will serve as an excellent guide for investors, researchers, consultants, marketing strategists, and all those who are planning to foray into the global biopharmaceutical market in any form.
What We Have Achieved in this Report?
Deep Qualitative Understanding of Various Factors Driving and Restraining the Global Biopharmaceutical Market
Key Aspects Analyzed:
Comprehensive Situation Analysis of the Global Biopharmaceutical Market and its Dynamics
North America: United States and Canada
Latin America: Mexico, Brazil and Argentina
Europe: Germany, France, Italy, Spain, United Kingdom, Russia and Turkey
Asia Pacific: Japan, China, Australia, South Korea, India and Indonesia
Classes Covered for Each Country: Erythropoietins, Insulin, Interferons, Growth Hormones, Immunoglobulins, Colony Stimulating Factors, Recombinant Blood Factors, Recombinant Enzymes, Growth Factors, Interleukins, Monoclonal Antibodies and Purified Proteins
Focus of the Analysis for Each Country:
Total Market Performance
Performance of Various Classes
Performance of Top Players
Key Questions Answered in this Report:
What are the key advantages/ disadvantages of biopharmaceuticals over small molecule drugs in terms of efficacy, safety, price, approval times, market growth, etc.?
What are the key opportunities and threats faced by the biopharmaceutical industry?
What has been the historical and current performance of the global biopharmaceutical market and how is it expected to perform in the coming years?
Which are the world's largest biopharmaceutical markets?
Which are the world's fastest growing biopharmaceutical markets?
What is the structure and composition of various biopharmaceutical markets across the globe?
Which are the world's largest biopharmaceutical segments?
Which are the world's fastest growing biopharmaceutical segments?
Who are the world's largest biopharmaceutical companies and how have they performed in recent years?
Download the full report: https://www.reportbuyer.com/product/1007821/
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information:
Research Advisor at Reportbuyer.com
Tel: +44 208 816 85 48
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-biopharmaceutical-market-report--forecast-2016-2021-300321100.html